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ABSTRACT  43 
OBJECTIVES: Low-dose aspirin is efficacious for the prevention of cardiovascular and 44 
cerebrovascular conditions, established risk factors for the onset of poor cognitive status and dementia. 45 
We investigated whether low-dose aspirin (i.e. a daily dosage <300 mg) can influence the onset of 46 
cognitive impairment/dementia in observational studies and improve cognitive tests scores in 47 
randomized controlled trials (RCTs) in participants without dementia. 48 
DESIGN: Systematic review and meta-analysis. 49 
SETTING: Observational and interventional studies.  50 
PARTICIPANTS: Subjects initially with no dementia/cognitive impairment.   51 
MEASUREMENTS: Odds ratios (ORs) and 95% confidence intervals (CIs), adjusted for the 52 
maximum number of covariates from each study were used to summarize data on the incidence of 53 
dementia/cognitive impairment. Standardized mean differences (SMDs) were used for cognitive test 54 
scores in RCTs.  55 
RESULTS: Of 2,341 initial hits, 8 studies were eligible and provided data for 36,196 participants 56 
without dementia/cognitive impairment at baseline (mean age 66 years, 63 % female). After adjusting 57 
for a median of 3 potential confounders, over a median follow-up period of 6 years, the use of low-dose 58 
chronic aspirin was not associated with a significant reduction in the onset of dementia or cognitive 59 
impairment (5 studies, N=26,159; OR=0.82; 95% CI [0.55,1.22]; p=0.33; I2=67%). In three RCTs 60 
(N=10,037; median follow-up=5 years), the use of low-dose aspirin was not associated with significant 61 
improvements in global cognition (SMD=0.005; 95% CI: [-0.04,0.05]; p=0.84; I2=0%) in individuals 62 
without dementia. Adherence was lower in aspirin compared to controls and the incidence of adverse 63 
events was higher.   64 
CONCLUSION: This review found no evidence that low-dose aspirin buffers against cognitive 65 
decline/ dementia or improves cognitive test scores in RCTs. 66 
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INTRODUCTION 68 
Low-dose aspirin is often used for the prevention of cardiovascular disease (CVD) due to its anti-69 
thrombotic properties.1,2 Aspirin has anti-inflammatory properties and inflammation plays a pivotal role 70 
in several diseases.4 Preclinical models suggest that aspirin may decrease neuroinflammation and 71 
oxidative stress in the central nervous system (CNS).5,6 These pleiotropic mechanisms of action of 72 
aspirin could aid in the prevention of cognitive decline or dementia.  73 
 74 
Cardiovascular and cerebrovascular conditions are established risk factors for poor cognitive status and 75 
dementia.7–9 The relationship between vascular disease and cognitive decline and dementia can 76 
explained by the atherosclerotic process leading to plaque development and reduced oxygen 77 
availability to the brain.10 Dementia and cardio- and cerebrovascular diseases share several risk factors, 78 
particularly with diabetes-mellitus.11,12 79 
 80 
There has been growing interest in the use of drugs of a similar nature to aspirin, such as nonsteroidal 81 
anti-inflammatory drugs (NSAIDs) for the prevention of dementia14. An increasing body of research is 82 
suggesting a potential role for aspirin in the prevention of poor cognitive status. Since dementia is 83 
irreversible, understanding if low-dose aspirin is useful for the prevention of cognitive decline and 84 
improvement of cognitive function of those without dementia is important. A Cochrane systematic 85 
review including one RCT (n=70) published 15 years ago demonstrated no benefit in aspirin preventing 86 
vascular-dementia.13 Since that time, further evidence has become available and an updated 87 
comprehensive meta-analysis is required.  88 
 89 
Given the aforementioned limitations in the literature, this paper had the following aims.  1) Investigate 90 
whether low-dose aspirin use is associated with the onset of dementia and poor cognitive status in 91 
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observational studies. 2) whether low-dose aspirin usage results in improved cognitive test scores in 92 
RCTs among people without cognitive impairment/dementia. We hypothesized that low-dose aspirin 93 
could have a favorable role on cognition.    94 
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METHODS 95 
This systematic review adhered to the PRISMA 16 and MOOSE 17 statements,  and followed an a priori 96 
defined, but unpublished protocol. 97 
 98 
Data sources and literature search strategy 99 
Two investigators (NV and MS) independently searched PubMed, EMBASE, SCOPUS, Cochrane 100 
Central Register of Controlled Trials and Clinicaltrials.gov without language restrictions, from 101 
database inception until September 1st, 2016.  Observational studies and RCTs investigating the effect 102 
of oral low-dose aspirin on the incidence of dementia and/or test scores assessing cognitive function in 103 
people without dementia/cognitive impairment at baseline were included. In PubMed, the following 104 
search strategy was used: (Aspirin OR acetylsalicylic acid) AND (cognit*). Conference abstracts and 105 
reference lists of included articles were hand-searched to identify any potential additional relevant 106 
articles. Any inconsistencies were resolved by consensus. 107 
 108 
Study selection  109 
Inclusion criteria for this meta-analysis were: i) use of an RCT or longitudinal study design; ii) use of 110 
low-dose aspirin (i.e. a daily dosage<300 mg18); iii) reporting data on dementia diagnosed through 111 
validated criteria; iv) reporting data of cognitive tests of global (e.g. mini-mental state examination, 112 
MMSE19) or specific cognitive functions in adults without dementia or cognitive impairment.  113 
 114 
Studies were excluded if: i) not conducted in humans; ii) used a non-placebo control group (active 115 
controls, in RCTs); iii) used dosages of aspirin with anti-inflammatory aims (i.e. with a dosage >300 116 
mg/daily or for brief periods, i.e. less than one year); iv) a standardized mean difference (SMD) or odds 117 
ratio (OR) could not be computed from the available data. If we encountered studies that did not 118 
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provide sufficient data for the meta-analysis, we contacted the authors twice over a month period to 119 
request additional data. 120 
 121 
Data extraction  122 
Two investigators (NV and BS) extracted data from the articles in a standardized file and a third 123 
independent investigator (MS) validated data extraction. We extracted data about authors, year of 124 
publication, country, setting, demographics (i.e. sample size, mean age and percentage of women), 125 
follow-up duration, diagnostic criteria or tests used for the diagnosis of dementia and cognitive 126 
impairment, daily dosage of aspirin. In longitudinal studies, we extracted the number and type of 127 
covariates used in the multivariate analyses. Moreover, we extracted data by treated with low-dose 128 
aspirin and controls. If information was missing, first and/or corresponding authors of the original 129 
article were contacted at least two times in a month.  130 
 131 
Outcomes 132 
For longitudinal studies, the primary outcome was the incidence of dementia or cognitive impairment 133 
during follow-up in the longitudinal studies. Dementia was ascertained through validated criteria, 134 
whilst cognitive impairment was ascertained according to predefined cut-offs of standardized tests for 135 
assessing cognitive status (i.e. a MMSE score < 24/30) 19.  136 
For RCTs, changes between follow-up and baseline of tests assessing cognition (such as global 137 
cognition, verbal memory or fluency) were extracted for participants without dementia or cognitive 138 
impairment at baseline in the group taking aspirin and in the control group (placebo/no intervention). 139 
 140 
 141 
 142 
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Assessment of study quality 143 
Two authors (NV, BS) assessed the quality of the studies using the Newcastle-Ottawa Scale (NOS) to 144 
evaluate longitudinal studies 20 and the Jadad’s scale21 for assessing the quality of the RCTs.  145 
 146 
Data synthesis and statistical analysis  147 
All analyses were performed using Comprehensive Meta-Analysis (CMA) 3 (http://www.meta-148 
analysis.com).  149 
 150 
In the primary analysis, we compared the data regarding the incidence of dementia and cognitive 151 
impairment in people using low-dose aspirin vs. no treatment using the ORs with their 95% confidence 152 
intervals (CIs), adjusted for the maximum number of covariates available for each study. In the co-153 
primary analysis, we compared cognitive tests values between participants treated with low dose 154 
aspirin vs. controls (placebo or no intervention). We calculated the difference between the means of the 155 
treatment and control groups, using the changes between follow-up and baseline data for each group, 156 
through SMD with 95% CIs. In all the analyses, a random-effect model was applied. 22 157 
 158 
Heterogeneity across studies was assessed by the I2 metric and Cochran’s Q chi-square statistics with a 159 
value>50% for the first and p <0.05 indicating the presence of a significant heterogeneity. 23  160 
 161 
Publication bias was assessed by visually inspecting funnel plots and the Begg-Mazumdar Kendall 162 
tau24 and the Egger bias test.25 To account for publication bias, we used the trim-and-fill method, to 163 
adjust for any potential unpublished (imputed) studies.26 164 
For all analyses, p<.05 was considered statistically significant.   165 
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RESULTS 166 
Search results 167 
Altogether, the search yielded 2,341 non-duplicated articles. After excluding 2,325 articles based on 168 
title/abstract review, 16 articles were retrieved for full text review and eight studies (5 longitudinal27–31  169 
and 3 RCTs 32–34) were included (Supplementary Figure S1). Overall eight studies were excluded 170 
since they included active controls (i.e. people taking another drug, n=3), investigated acute effects of 171 
aspirin on cognition (i.e. a daily dose over 300 mg used for analgesic aims, n=2), were reviews (n=1),a 172 
protocol (n=1) or reported data as linear regression estimates, thus not meta-analyzable (n=1). 173 
 174 
Study and participants’ characteristics  175 
Full descriptive details of the included studies are reported in Supplementary Tables S 1-2.  176 
 177 
This meta-analysis included 36,196 participants, of which 8,484 (23.4%) received low-dose aspirin. 178 
The mean age was 66 years and the participants were mainly women (63%). All the studies were 179 
conducted among community-dwellers and in Europe (6 studies) or USA (2 studies).  180 
 181 
Longitudinal studies 182 
The five longitudinal studies27–31 included 26,159 community-dwelling participants with a mean age of 183 
65.1 years, mainly women for a median follow-up period of 6 years. Three studies27,29,30 investigated 184 
dementia as outcome, whilst the other two28,31 considered cognitive impairment (Supplementary 185 
Table S1). The quality of the studies was sufficient (NOS mean 6, 6-7)..20 186 
Among the 26,159 participants, 3035 (11.6%) used low-dose aspirin. The participants using low-dose 187 
aspirin at baseline were significantly older (78.1±5.3 vs. 75.9±6.4 years, p<0.0001), whilst no 188 
differences emerged regarding the percentage of women (64% vs. 69%, p=0.15).  189 
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RCTs 190 
The three RCTs32–34 (two versus placebo32,34 and one33 as add-on therapy) included 10,037 participants 191 
aged on average 66.8 years, mainly women (74%). The median follow-up period was 5 years (range: 3-192 
9.6). One RCT33 used the MMSE score as tool for cognitive status, whilst the other two32,34 used 193 
several tests, as shown in Supplementary Table S2.  The quality of the studies was good.21  194 
 195 
Meta-analysis of longitudinal studies 196 
After adjusting for a median of 3 potential confounders (range: 0-7), the use of low-dose aspirin was 197 
not associated with any significant reduction in the onset of dementia or cognitive impairment (5 198 
studies; OR=0.82; 95%CI: 0.55-1.22; p=0.33; I2=67%; Figure 1). Considering each study separately, 199 
only one study 29 with the largest cohort available (n=23,915 participants at baseline) reported a 200 
significant decreased risk of dementia at follow-up, taking in account also 4 potential confounders (see 201 
Supplementary Table S2). Even though the three studies using dementia as outcome27,29,30 reported a 202 
lower OR, (0.59 (95%CI: 0.33-1.05; p=0.84; I2=33%) than the other two which examined cognitive 203 
impairment28,31 [OR=0.96 (95%CI: 0.62-1.51; p=0.66; I2=59%)], the interaction of aspirin use by 204 
outcome was not significant (p=0.18). After removing one study30 (a conference abstract) the results 205 
did not significantly change (OR=0.72; 95%CI: 0.47-1.10; p=0.14; I2=70%), with the studies assessing 206 
dementia reporting an OR=0.59 (95%CI: 0.33-1.05; p=0.07; I2=33%).  207 
 208 
Meta-analysis of randomized controlled trials 209 
As reported in Figure 2, the use of low-dose aspirin was not associated with any improvement in 210 
global cognitive tests in the three RCTs including 10,037 participants32–34 (SMD=0.00; 95%CI: -0.04 to 211 
0.05; p=0.84; I2=0%). Publication bias was unlikely.   212 
 213 
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Two studies 32,34 reported information regarding verbal memory and executive function/fluency tests. 214 
Whilst no significant differences emerged in terms of verbal memory tests (SMD=-0.02; 95%CI: -0.06 215 
to 0.03; p=0.42; I2=0%), the use of low-dose aspirin was associated with a significant small 216 
improvement in executive function/fluency tests (SMD=0.06; 95%CI: 0.02 to 0.11; p=0.006; I2=0%). 217 
This improvement was estimated to correspond to 2.6 years younger age, and a substantial 20% lower 218 
risk of cognitive decline compared to the use of placebo34 in a single study. 219 
 220 
Compliance and adverse effects 221 
In the three RCTs included, a lower percentage of participants using low-dose aspirin completed the 222 
RCTs compared to controls (69.9 vs. 75.9%, chi-square test p-value=0.005).  223 
 224 
Only two studies (one longitudinal 27 and one RCT 33) reported information regarding side effects. The 225 
prevalence of gastrointestinal adverse events was ten times higher in people taking aspirin compared to 226 
controls (15.2% vs. 1.4%, p<0.0001). Whilst the RCT33 did not report the type of gastrointestinal side 227 
effects, the longitudinal study27 reported a similar incidence of gastric ulcers between those taking and 228 
not taking aspirin (p=0.17).      229 
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DISCUSSION 230 
In this meta-analysis, we found that the use of low-dose aspirin did not appear to be associated with a 231 
lower incidence of dementia and cognitive impairment in observational studies. Across RCTs, we 232 
found no evidence of improvement in cognitive test scores among people who were free from dementia 233 
or cognitive impairment. However, people using low-dose aspirin experienced a higher frequency of 234 
side effects (particularly gastrointestinal), although this information is limited to data from two studies.  235 
 236 
Several hypotheses might explain these findings. First, the average age of the participants was 65 years. 237 
Previous research has suggested that the pathological changes typical of dementia happen 20 years 238 
before the clinical symptoms present 35, therefore the use of low-dose aspirin at this age may be ‘too 239 
little and/or too late’.  Second, participants may have been taking low dose aspirin for the secondary 240 
prevention of CVD or related conditions. Thus, pre-existing comorbidities at baseline may have 241 
interfered with low dose aspirins potential cognitive beneficial effects and explain the null result. 242 
Finally, genetic factors could play a role in this lack of effect of low-dose aspirin. One study 243 
investigated if the role of the APOE gene altered the association between nonsteroidal anti-244 
inflammatory drug (NSAID) use and dementia risk, and found reduced risk of AD only in NSAID 245 
users with an APOE epsilon 4 allele.37 Specific research is needed to clarify this potential hypothesis. 246 
Other factors may have accounted for our result across RCTs which also need to be considered. First, 247 
the number of people lost during follow-up could have influenced our results. Moreover, some of the 248 
cognitive tests, such as the MMSE, suffer from important limitations, such as the over estimation of 249 
cognitive impairments in persons over age 60 and in those with lower educational status.38 In our meta-250 
analysis, we tried to overcome this issue by using all of the tests available that assessed cognition and 251 
subcomponents such as executive function/fluency tests which may be improved by aspirin use. 252 
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However, the very small effect size detected in the latter suggests that the clinical significance of these 253 
findings is probably limited.  254 
 255 
Our findings are in partial agreement with two recent meta-analyses considering the use of other 256 
NSAIDs on cognitive outcomes. While the use of NSAIDs was associated with a 28% decrease in 257 
dementia onset in the longitudinal studies14, the findings from the RCTs did not support these 258 
observational findings.39 Taken together, it appears there is no consistent evidence that the use of 259 
NSAIDs may delay or prevent the onset of either dementia or cognitive impairment over time.  260 
However future, adequately powered real world investigations are required to better understand if 261 
aspirin and other NSAIDs can delay or prevent dementia. Based on our findings, we suggest that future 262 
RCTs including more men and younger people are probably needed. In this context, the ASPREE 263 
(ASPirin in Reducing Events in the Elderly) study, an ongoing trial including 19,000 healthy 264 
participants aged 65 years and above could be of importance for better understanding the possible role 265 
of aspirin in the prevention of dementia and mild cognitive impairment.40 However, particular attention 266 
should also be given to adherence and any adverse events from such studies and low cost and lower 267 
risk alternatives such as physical activity41,42 and nutrition interventions43 should also be considered in 268 
this regard.  269 
Although few studies provided evidence on adherence and adverse events, the limited available 270 
evidence suggests that lower adherence could in part be explained by a higher incidence of adverse 271 
events. Gastrointestinal side effects appear to be particularly troublesome. Some experts have 272 
suggested that aspirin may lead to an increase in gut permeability (i.e. ‘leaky gut’), which may lead to 273 
the translocation of bacterial products (e.g. lipopolysaccharide-LPS), which may increase microglial 274 
activation and therefore neuroinflammation.6,44,45 Bearing in mind the possible limitations of our work, 275 
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these results suggest not only a lack of evidence that aspirin could protect against cognitive 276 
decline/dementia, but that it may increase adverse gastrointestinal events.  277 
 278 
The findings of our meta-analysis should be interpreted within its limitations. First, we only identified a 279 
limited number of the RCTs. Although these studies were of high quality, with a large sample size and 280 
long follow-up period, other studies are needed to have a definitive conclusion. Second, the 281 
observational studies did not use the propensity score in their analyses which is the best method for 282 
comparing a population taking a drug with another one without.46 Moreover, the possibility of a 283 
selection bias in longitudinal studies and the fact that a consistent percentage of people not taking 284 
aspirin took other NSAIDs might create another important bias in our results. Moreover, one study 285 
included the overwhelming majority of participants and thus could have had a large influence on the 286 
overall result.28 Another limitation is the high heterogeneity observed in the longitudinal studies and 287 
that no meta-regression analysis was possible due to the limited number of studies for each outcome.47 288 
Fourth, no study assessed the effect of low-dose aspirin in reducing dementia risk by APOE epsilon 4 289 
status, which this could be a relevant factor in establishing a link between aspirin use and cognitive 290 
decline. It may be possible that only people with this mutation had a reduced risk of dementia when 291 
taking aspirin as shown by a large study analyzing the interaction between APOE epsilon 4 status and 292 
NSAIDs.37 Fifth, conclusions on side effects of aspirin are based on only two studies. Finally, although 293 
we accounted for potential confounding factors when data were available by using adjusted effect 294 
estimates in our pooled analyses, it was not possible to consider other potentially important, 295 
unidentified confounders.  For instance, people on low-dose aspirin are more likely to be at risk of, or 296 
with a history of CVDs than those not on aspirin, and the indications for aspirin may vary across 297 
countries, and these may be influential factors. Thus, future research should attempt to consider, where 298 
possible, the impact of such factors on the relationship between aspirin and cognitive outcomes. 299 
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The strengths of our work includes a comprehensive search of several databases, and the inclusion of 300 
the largest possible number of participants, the long follow-up of each study and that, to the best of our 301 
knowledge, this is the first systematic review and meta-analysis to consider this issue.  302 
 303 
In conclusion, our preliminary meta-analysis suggests that low-dose aspirin does not decrease the risk 304 
of poor cognitive status (in terms of dementia or cognitive impairment) nor improve cognitive tests in 305 
randomized controlled trials. Moreover, adherence to aspirin may be lower compared to control 306 
conditions and adverse events may be more common. Future trials, considering dementia onset as 307 
outcome, are needed to disentangle if low-dose aspirin could be used to improve cognitive status, and 308 
to test the possibility that low-dose aspirin has beneficial effects when taken over a longer period and at 309 
an earlier age than the observed population did.  310 
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